Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation

Varsha Vakil, Joanna J. Sung, Marta Piecychna, Jeffrey R. Crawford, Phillip H Kuo, Ali K. Abu-Alfa, Shawn E. Cowper, Richard Bucala, Richard H. Gomer

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Gadolinium-containing magnetic resonance imaging (MRI) contrast agents such as Omniscan are associated with nephrogenic systemic fibrosis (NSF). To determine if Omniscan can affect the differentiation of monocytes into fibroblast-like cells called fibrocytes that are found in the fibrotic lesions of NSF, peripheral blood mononuclear cells (PBMCs) from NSF patients, hemodialysis patients without NSF, and healthy, renally sufficient controls were exposed to Omniscan in a standardized in vitro fibrocyte differentiation protocol. When added to PBMCs, the gadolinium-containing MRI contrast agent Omniscan generally had little effect on fibrocyte differentiation. However, 10-8 to 10-3 mg/mL Omniscan reduced the ability of the fibrocyte differentiation inhibitor serum amyloid P (SAP) to decrease fibrocyte differentiation in PBMCs from 15 of 17 healthy controls and one of three NSF patients. Omniscan reduced the ability of SAP to decrease fibrocyte differentiation from purified monocytes, indicating that the Omniscan effect does not require the presence of other cells (such as T cells) in the PBMCs. Omniscan also reduced the ability of a different fibrocyte differentiation inhibitor, interleukin-12, to decrease fibrocyte differentiation. These data suggest that Omniscan interferes with the regulatory action of signals that inhibit the differentiation of monocytes to fibrocytes.

Original languageEnglish (US)
Pages (from-to)1284-1288
Number of pages5
JournalJournal of Magnetic Resonance Imaging
Volume30
Issue number6
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

gadodiamide
Gadolinium
Contrast Media
Nephrogenic Fibrosing Dermopathy
Magnetic Resonance Spectroscopy
Blood Cells
Monocytes
Amyloid
Magnetic Resonance Imaging

Keywords

  • IL-12
  • Monocytes
  • Nephrogenic systemic fibrosis
  • Omniscan
  • Peripheral blood mononuclear cells
  • Serum amyloid P

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Vakil, V., Sung, J. J., Piecychna, M., Crawford, J. R., Kuo, P. H., Abu-Alfa, A. K., ... Gomer, R. H. (2009). Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Journal of Magnetic Resonance Imaging, 30(6), 1284-1288. https://doi.org/10.1002/jmri.21800

Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. / Vakil, Varsha; Sung, Joanna J.; Piecychna, Marta; Crawford, Jeffrey R.; Kuo, Phillip H; Abu-Alfa, Ali K.; Cowper, Shawn E.; Bucala, Richard; Gomer, Richard H.

In: Journal of Magnetic Resonance Imaging, Vol. 30, No. 6, 12.2009, p. 1284-1288.

Research output: Contribution to journalArticle

Vakil, V, Sung, JJ, Piecychna, M, Crawford, JR, Kuo, PH, Abu-Alfa, AK, Cowper, SE, Bucala, R & Gomer, RH 2009, 'Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation', Journal of Magnetic Resonance Imaging, vol. 30, no. 6, pp. 1284-1288. https://doi.org/10.1002/jmri.21800
Vakil, Varsha ; Sung, Joanna J. ; Piecychna, Marta ; Crawford, Jeffrey R. ; Kuo, Phillip H ; Abu-Alfa, Ali K. ; Cowper, Shawn E. ; Bucala, Richard ; Gomer, Richard H. / Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. In: Journal of Magnetic Resonance Imaging. 2009 ; Vol. 30, No. 6. pp. 1284-1288.
@article{e84e6fa5a8914429913ffc20d53eb032,
title = "Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation",
abstract = "Gadolinium-containing magnetic resonance imaging (MRI) contrast agents such as Omniscan are associated with nephrogenic systemic fibrosis (NSF). To determine if Omniscan can affect the differentiation of monocytes into fibroblast-like cells called fibrocytes that are found in the fibrotic lesions of NSF, peripheral blood mononuclear cells (PBMCs) from NSF patients, hemodialysis patients without NSF, and healthy, renally sufficient controls were exposed to Omniscan in a standardized in vitro fibrocyte differentiation protocol. When added to PBMCs, the gadolinium-containing MRI contrast agent Omniscan generally had little effect on fibrocyte differentiation. However, 10-8 to 10-3 mg/mL Omniscan reduced the ability of the fibrocyte differentiation inhibitor serum amyloid P (SAP) to decrease fibrocyte differentiation in PBMCs from 15 of 17 healthy controls and one of three NSF patients. Omniscan reduced the ability of SAP to decrease fibrocyte differentiation from purified monocytes, indicating that the Omniscan effect does not require the presence of other cells (such as T cells) in the PBMCs. Omniscan also reduced the ability of a different fibrocyte differentiation inhibitor, interleukin-12, to decrease fibrocyte differentiation. These data suggest that Omniscan interferes with the regulatory action of signals that inhibit the differentiation of monocytes to fibrocytes.",
keywords = "IL-12, Monocytes, Nephrogenic systemic fibrosis, Omniscan, Peripheral blood mononuclear cells, Serum amyloid P",
author = "Varsha Vakil and Sung, {Joanna J.} and Marta Piecychna and Crawford, {Jeffrey R.} and Kuo, {Phillip H} and Abu-Alfa, {Ali K.} and Cowper, {Shawn E.} and Richard Bucala and Gomer, {Richard H.}",
year = "2009",
month = "12",
doi = "10.1002/jmri.21800",
language = "English (US)",
volume = "30",
pages = "1284--1288",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation

AU - Vakil, Varsha

AU - Sung, Joanna J.

AU - Piecychna, Marta

AU - Crawford, Jeffrey R.

AU - Kuo, Phillip H

AU - Abu-Alfa, Ali K.

AU - Cowper, Shawn E.

AU - Bucala, Richard

AU - Gomer, Richard H.

PY - 2009/12

Y1 - 2009/12

N2 - Gadolinium-containing magnetic resonance imaging (MRI) contrast agents such as Omniscan are associated with nephrogenic systemic fibrosis (NSF). To determine if Omniscan can affect the differentiation of monocytes into fibroblast-like cells called fibrocytes that are found in the fibrotic lesions of NSF, peripheral blood mononuclear cells (PBMCs) from NSF patients, hemodialysis patients without NSF, and healthy, renally sufficient controls were exposed to Omniscan in a standardized in vitro fibrocyte differentiation protocol. When added to PBMCs, the gadolinium-containing MRI contrast agent Omniscan generally had little effect on fibrocyte differentiation. However, 10-8 to 10-3 mg/mL Omniscan reduced the ability of the fibrocyte differentiation inhibitor serum amyloid P (SAP) to decrease fibrocyte differentiation in PBMCs from 15 of 17 healthy controls and one of three NSF patients. Omniscan reduced the ability of SAP to decrease fibrocyte differentiation from purified monocytes, indicating that the Omniscan effect does not require the presence of other cells (such as T cells) in the PBMCs. Omniscan also reduced the ability of a different fibrocyte differentiation inhibitor, interleukin-12, to decrease fibrocyte differentiation. These data suggest that Omniscan interferes with the regulatory action of signals that inhibit the differentiation of monocytes to fibrocytes.

AB - Gadolinium-containing magnetic resonance imaging (MRI) contrast agents such as Omniscan are associated with nephrogenic systemic fibrosis (NSF). To determine if Omniscan can affect the differentiation of monocytes into fibroblast-like cells called fibrocytes that are found in the fibrotic lesions of NSF, peripheral blood mononuclear cells (PBMCs) from NSF patients, hemodialysis patients without NSF, and healthy, renally sufficient controls were exposed to Omniscan in a standardized in vitro fibrocyte differentiation protocol. When added to PBMCs, the gadolinium-containing MRI contrast agent Omniscan generally had little effect on fibrocyte differentiation. However, 10-8 to 10-3 mg/mL Omniscan reduced the ability of the fibrocyte differentiation inhibitor serum amyloid P (SAP) to decrease fibrocyte differentiation in PBMCs from 15 of 17 healthy controls and one of three NSF patients. Omniscan reduced the ability of SAP to decrease fibrocyte differentiation from purified monocytes, indicating that the Omniscan effect does not require the presence of other cells (such as T cells) in the PBMCs. Omniscan also reduced the ability of a different fibrocyte differentiation inhibitor, interleukin-12, to decrease fibrocyte differentiation. These data suggest that Omniscan interferes with the regulatory action of signals that inhibit the differentiation of monocytes to fibrocytes.

KW - IL-12

KW - Monocytes

KW - Nephrogenic systemic fibrosis

KW - Omniscan

KW - Peripheral blood mononuclear cells

KW - Serum amyloid P

UR - http://www.scopus.com/inward/record.url?scp=73649131651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649131651&partnerID=8YFLogxK

U2 - 10.1002/jmri.21800

DO - 10.1002/jmri.21800

M3 - Article

C2 - 19937928

AN - SCOPUS:73649131651

VL - 30

SP - 1284

EP - 1288

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 6

ER -